​

EVOQ Therapeutics is pioneering the development of a proprietary technology that represents a genuine breakthrough for autoimmune disease therapy.

​

Autoimmune Disease Vaccines

​

EVOQ's technology has demonstrated breakthrough efficacy in the gold-standard preclinical models of Multiple Sclerosis (MS) and Type-1 Diabetes (T1D). Success with these preclinical models  is considered proof of concept for the potential utility of a therapy in a wide range of autoimmune diseases.

​

With prevalence on the rise, autoimmune diseases have a devastating impact on the lives of 23.5 million Americans, and millions  more of children and adults around the world.

​

Examples include:

• Type 1 Diabetes

• Celiac disease

• Multiple sclerosis

• Neuromyelitis optica

• Rheumatoid arthritis

• Myasthenia gravis

• Pemphigus

• Graves' disease

​

EVOQ's technology utilizes a proprietary synthetic HDL NanoDisc that has been optimized to deliver antigens to dendritic cells residing in lymph nodes.

​